RxDoctor Payments Data

Anastasiya Zakharova

Physician Assistant · Sacramento, CANPI 1912509084

Payments from drug & device makers

$1,923in general payments, 2019–2025

Across 97 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$492
  • Otsuka America Pharmaceutical, Inc.$228
  • Alkermes, Inc.$224
  • Sunovion Pharmaceuticals Inc.$193
  • AbbVie$184
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$155
  • plus $447 from 8 others

What the payments were for

  • Food & beverage$1,923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,923 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$23,896
Medicare patients
48
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$19,566
Lurasidone Hcl30$18,298
Paliperidone ErPaliperidone16$6,389
Aripiprazole56$2,065
Quetiapine Fumarate63$1,585
Divalproex Sodium ErDivalproex Sodium23$1,557
Trazodone Hcl74$1,214
Methylphenidate Er (La)Methylphenidate Hcl14$1,141
Fluvoxamine Maleate16$996
Prazosin Hcl19$889
Thioridazine Hcl11$758
Venlafaxine Hcl ErVenlafaxine Hcl57$693
Escitalopram Oxalate35$677
Gabapentin22$628
Hydroxyzine Hcl34$614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$184$19,56612 claims
Almatica Pharma LLCSertraline Hcl$14$10920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →